SG11201504067SA - Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient - Google Patents

Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient

Info

Publication number
SG11201504067SA
SG11201504067SA SG11201504067SA SG11201504067SA SG11201504067SA SG 11201504067S A SG11201504067S A SG 11201504067SA SG 11201504067S A SG11201504067S A SG 11201504067SA SG 11201504067S A SG11201504067S A SG 11201504067SA SG 11201504067S A SG11201504067S A SG 11201504067SA
Authority
SG
Singapore
Prior art keywords
active ingredient
solid dispersion
improved solubility
tetrazole derivative
tetrazole
Prior art date
Application number
SG11201504067SA
Inventor
Yong Il Kim
Jun Young Choi
Young Keun Choi
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11201504067SA publication Critical patent/SG11201504067SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
SG11201504067SA 2012-12-13 2013-12-12 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient SG11201504067SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120145603A KR101986683B1 (en) 2012-12-13 2012-12-13 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
PCT/KR2013/011545 WO2014092489A1 (en) 2012-12-13 2013-12-12 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient

Publications (1)

Publication Number Publication Date
SG11201504067SA true SG11201504067SA (en) 2015-06-29

Family

ID=50934681

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504067SA SG11201504067SA (en) 2012-12-13 2013-12-12 Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient

Country Status (38)

Country Link
US (1) US9283218B2 (en)
EP (1) EP2931720B1 (en)
JP (1) JP6355645B2 (en)
KR (1) KR101986683B1 (en)
CN (1) CN104870443B (en)
AR (2) AR093706A1 (en)
AU (1) AU2013360544B2 (en)
BR (1) BR112015013905A2 (en)
CA (1) CA2892376C (en)
CL (1) CL2015001551A1 (en)
CR (1) CR20150361A (en)
DK (1) DK2931720T3 (en)
DO (1) DOP2015000128A (en)
EC (1) ECSP15029808A (en)
ES (1) ES2731806T3 (en)
GT (1) GT201500123A (en)
HK (1) HK1212330A1 (en)
HU (1) HUE044659T2 (en)
IL (1) IL239327A (en)
JO (1) JO3534B1 (en)
LT (1) LT2931720T (en)
MX (1) MX363644B (en)
MY (1) MY174746A (en)
NI (1) NI201500073A (en)
NZ (1) NZ709071A (en)
PE (1) PE20151066A1 (en)
PH (1) PH12015501312A1 (en)
PL (1) PL2931720T3 (en)
PT (1) PT2931720T (en)
RU (1) RU2662819C2 (en)
SA (1) SA515360535B1 (en)
SG (1) SG11201504067SA (en)
SI (1) SI2931720T1 (en)
TR (1) TR201908746T4 (en)
TW (1) TWI652073B (en)
UY (1) UY35186A (en)
WO (1) WO2014092489A1 (en)
ZA (1) ZA201503795B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102044223B1 (en) * 2016-09-12 2019-11-13 성균관대학교산학협력단 Solid dispersions comprising Telmisartan and the preparation method thereof
CN111867562B (en) * 2018-03-07 2023-07-07 陈献 Aqueous formulation of insoluble drug
CZ2018188A3 (en) * 2018-04-18 2019-10-30 Zentiva, K.S. Amorphous empagliflozin particles, process for preparing them and pharmaceutical preparation
EP3893867A1 (en) 2018-12-14 2021-10-20 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer
WO2020124070A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
WO2020168144A1 (en) 2019-02-14 2020-08-20 Teva Pharmaceuticals International Gmbh Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2022011221A1 (en) 2020-07-10 2022-01-13 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
TW202233593A (en) 2020-10-07 2022-09-01 美商亞瑟尼克斯公司 Acetamido-phenyltetrazole derivatives and methods of using the same
JP2023548384A (en) 2020-10-30 2023-11-16 アテネックス アールアンドディ エルエルシー Polymorphism of HM30181 mesylate salt

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP2000309588A (en) * 1999-04-28 2000-11-07 Taisho Pharmaceut Co Ltd Solid dispersing element
RU2006102981A (en) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) MEDICINAL FORMS FOR CONTROLLABLE RELEASE OF PROTEIN-TRANSFER INHIBITORS OF CHOLESTEROL ETHERS AND IMMEDIATE RELEASE OF HMG-СОА-REductase INHIBITORS
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
KR100557093B1 (en) * 2003-10-07 2006-03-03 한미약품 주식회사 Tetrazole derivatives having inhibitory activity against multi-drug resistance and preparation thereof
KR100572411B1 (en) 2003-10-23 2006-04-18 한미약품 주식회사 Thermodynamic stable amorphous torasemide solid dispersions and pharmaceutical composition comprising same and method for the preparation thereof
MX2007004973A (en) 2004-10-25 2007-06-14 Japan Tobacco Inc Solid medicinal preparation improved in solubility and stability and process for producing the same.
KR100678824B1 (en) * 2005-02-04 2007-02-05 한미약품 주식회사 Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same
SI1926476T1 (en) * 2005-08-29 2013-07-31 Sanofi-Aventis U.S. Llc Amorphous solid dispersions of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5,-dihydro-4h-pyridazinos4,5-bcindole-1-acetamide
KR101466245B1 (en) * 2010-01-15 2014-12-01 한미사이언스 주식회사 Method for preparing methanesulfonic acid salt and novel compound used therein
KR20110132116A (en) * 2010-06-01 2011-12-07 (주)국전약품 Solid dispersion comprising raloxifene hydrochloride, manufacturing method thereof, and oral dosage form comprising the solid dispersion
US8557995B2 (en) * 2010-06-09 2013-10-15 Abbvie Inc. Solid dispersions containing kinase inhibitors

Also Published As

Publication number Publication date
KR20140076979A (en) 2014-06-23
UY35186A (en) 2014-07-31
PH12015501312B1 (en) 2015-08-24
AR123783A2 (en) 2023-01-11
WO2014092489A1 (en) 2014-06-19
NI201500073A (en) 2016-01-06
AU2013360544B2 (en) 2017-05-11
SI2931720T1 (en) 2019-08-30
RU2662819C2 (en) 2018-07-31
LT2931720T (en) 2019-07-10
TWI652073B (en) 2019-03-01
CN104870443B (en) 2018-09-14
CA2892376A1 (en) 2014-06-19
NZ709071A (en) 2019-08-30
US20150272943A1 (en) 2015-10-01
ES2731806T3 (en) 2019-11-19
EP2931720A1 (en) 2015-10-21
ECSP15029808A (en) 2016-01-29
HUE044659T2 (en) 2019-11-28
PE20151066A1 (en) 2015-08-11
GT201500123A (en) 2018-10-08
HK1212330A1 (en) 2016-06-10
EP2931720A4 (en) 2016-06-29
CR20150361A (en) 2015-08-21
ZA201503795B (en) 2016-08-31
MX363644B (en) 2019-03-29
IL239327A0 (en) 2015-07-30
IL239327A (en) 2017-11-30
EP2931720B1 (en) 2019-04-24
US9283218B2 (en) 2016-03-15
TW201429507A (en) 2014-08-01
CA2892376C (en) 2020-10-27
MY174746A (en) 2020-05-13
PT2931720T (en) 2019-06-25
SA515360535B1 (en) 2017-07-17
KR101986683B1 (en) 2019-06-10
DOP2015000128A (en) 2015-09-30
PH12015501312A1 (en) 2015-08-24
AU2013360544A1 (en) 2015-07-09
CN104870443A (en) 2015-08-26
JP6355645B2 (en) 2018-07-11
BR112015013905A2 (en) 2017-07-11
DK2931720T3 (en) 2019-07-08
JP2016507489A (en) 2016-03-10
CL2015001551A1 (en) 2015-09-25
MX2015006416A (en) 2015-08-14
AR093706A1 (en) 2015-06-17
PL2931720T3 (en) 2019-09-30
JO3534B1 (en) 2020-07-05
RU2015128002A (en) 2017-01-16
TR201908746T4 (en) 2019-07-22

Similar Documents

Publication Publication Date Title
HK1212330A1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
TWI561171B (en) Active compound combinations
PL2836072T3 (en) Herbicidal composition comprising an uracil compound as active ingredient
HUE039664T2 (en) N-arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
IL238328A0 (en) Stable peracid-containing compositions
ZA201308371B (en) Sustained release pheromone formulation
ZA201504520B (en) Active ingredient microparticles
ZA201306000B (en) Stable formulation
HK1205679A1 (en) Nicotine formulation
PT2908835T (en) Stable formulations
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
GB201320585D0 (en) Insecticidal compounds based on arylthiosulfonamide derivatives
HK1180461A1 (en) Chopping amplifier
GB201210530D0 (en) Extended release formulations
EP2920475A4 (en) Active bolt release arrangement
IL234771A0 (en) Nicotine formulation
PT2934506T (en) Glutamate derivatives for topical use as immunomodulatory active ingredient
AU2012903717A0 (en) Stabilizing drawbar mounting device
AU2012904552A0 (en) An Improved Towball